Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A recent Phase 2 randomised placebo-controlled trial tested efinopegdutide in people with obesity over a 26-week period, where participants were randomly assigned weekly treatment with either placebo, 5 mg, 7.4 mg, 10 mg efinopegdutide, or 3 mg liraglutide daily
Many practitioners prefer the no-DAC version specifically because it produces sharp GH pulses that more closely mimic natural physiology
And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier
What are the options
Based on current evidence, oral supplements have a stronger scientific foundation
Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
